

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer

Seigo Minami
Yoshitaka Ogata
Shouichi Ihara
Suguru Yamamoto
Kiyoshi Komuta

Department of Respiratory Medicine,
Osaka Police Hospital, Osaka, Japan

Background: Various biomarkers have been shown to predict prognosis in various types of cancers. However, these biomarkers have not been studied in advanced small cell lung cancer (SCLC). The modified Glasgow prognostic score (mGPS) is based on serum albumin level and C-reactive protein (CRP). The prognostic nutritional index (PNI) is a combination of serum albumin level and absolute lymphocyte count. This study aimed to evaluate the prognostic value of mGPS and PNI in SCLC.

Methods: We retrospectively reviewed and calculated mGPS and PNI for patients with stage IIIB or IV SCLC who initiated platinum-based combination chemotherapy between November 2007 and June 2016. We compared overall survival (OS) and progression-free survival (PFS) between high and low groups of these two biomarkers. Univariate and multivariate Cox hazard analyses assessed the prognostic value of these biomarkers.

Results: We reviewed 97 SCLC patients. The OS of patients with mGPS 0–1 and higher PNI was significantly longer than that of those with mGPS 2 and lower PNI. The PFS of mGPS 0–1 was significantly longer than that of mGPS 2, while there was no significant difference in PFS according to PNI. Multivariate analyses found mGPS 0–1 (hazard ratio [HR] 2.34, 95% confidence interval [CI] 1.27–4.31, $P < 0.01$) and higher PNI (HR 0.50, 95% CI 0.31–0.78, $P < 0.01$) as prognostic factors for longer OS. However, neither biomarker was predictive of PFS.

Conclusion: Our study was a small retrospective study; however, the data demonstrate that pretreatment mGPS and PNI are independent predictors of OS in patients with advanced SCLC. The pretreatment assessment of mGPS and PNI may be useful for identification of patients with poor prognosis. We recommend pretreatment measurement of serum albumin, C-reactive protein, and absolute lymphocyte count.

Keywords: small cell lung cancer, modified Glasgow prognostic score, prognostic nutritional index, overall survival, progression-free survival

Introduction

The incidence of small cell lung cancer (SCLC) has been declining in Japan, but still accounts for 10%–15% of lung cancer cases.¹ The majority of Japanese patients with lung cancer are diagnosed when the disease has already become regionally advanced or metastatic. SCLC is characterized by aggressive progression, early metastases and poor prognosis, despite being highly sensitive to chemotherapy.

Complex diagnostic and prognostic tools are cumbersome to use in clinical practice; clinicians require tools that are simple and straightforward. Recently, various

Correspondence: Seigo Minami
Department of Respiratory Medicine,
Osaka Police Hospital, 10-31 Kitayama-
cho, Tennoji-ku, Osaka-City, Osaka
543-0035, Japan
Tel +81 66 771 6051
Fax +81 66 771 2838
Email seigominami@oph.gr.jp

laboratory biomarkers have been developed based on systemic inflammation or nutritional status. These biomarkers have been demonstrated to predict prognosis in various cancers.

The modified Glasgow prognostic score (mGPS)²⁻⁴ is based on a combination of serum albumin level and C-reactive protein (CRP). The prognostic nutritional index (PNI)⁵ is based on a combination of serum albumin level and absolute lymphocyte count. These two tools have been shown to predict prognosis for many solid tumors. In contrast to a large number of studies for non-SCLC, there have been only a few studies that report validated mGPS⁶ and PNI^{7,8} for SCLC. These studies included patients at various stages of disease, undergoing various treatment protocols.

This study aimed to evaluate these two prognostic biomarkers for patients with advanced SCLC who had received platinum-based combination chemotherapy.

Patients and methods

Patient selection and study design

We retrospectively selected patients who met all the following criteria: 1) histologically or cytologically diagnosed SCLC; 2) clinical stage IIIB or IV in the seventh TNM classification of lung cancer by the Union for International Cancer Control,⁹ because our practice did not adopt the staging system of the Veterans Administration Lung Study Group;¹⁰ 3) initiation of platinum-based combination regimen as the first-line chemotherapy between November 2007 and June 2016 at our institution, and 4) available pretreatment blood test and sufficient laboratory data. The exclusion criteria were as follows: 1) patients who had received non-platinum chemotherapy as the first-line therapy; 2) patients who had received concurrent or sequential curative-intent thoracic radiotherapy, though we accepted patients with concurrent palliative radiotherapy, and 3) patients who had initiated chemotherapy at other institutions and thereafter transferred to our hospital.

Baseline characteristics included sex, age, clinical stage, Eastern Cooperative Oncology Group Performance Status (ECOG-PS),¹¹ smoking status, height, body weight and therapeutic data. Current smokers were arbitrarily defined as patients who had smoked within a year prior to the diagnosis. Pretreatment laboratory data obtained within 2 weeks prior to chemotherapy included: complete blood count, hemoglobin, red cell distribution width, creatinine clearance estimated by Cockcroft–Gault formula with addition of 0.2 mg/dL to serum creatinine concentration,¹² serum albumin, sodium concentration, lactate dehydro-

genase (LDH), alkaline phosphatase (ALP) and CRP. PNI was calculated according to the following formula as previously described:⁵ $10 \times \text{serum albumin value (g/dL)} + 0.005 \times \text{peripheral lymphocyte count (/}\mu\text{L)}$. Elevated CRP and hypoalbuminemia were combined to generate the mGPS. If CRP was >1.0 mg/dL and albumin <3.5 g/dL, we assigned a score of 2; CRP >1.0 mg/dL only was assigned a score of 1 and absence of these two abnormalities was assigned a score of 0.¹³ Progression-free survival (PFS) and overall survival (OS) were calculated from the first day of chemotherapy to the date of documented progressive disease or death. Response to chemotherapy was based on Response Evaluation Criteria in Solid Tumors version 1.1.¹⁴ The data cut-off date was March 31, 2017.

The Osaka Police Hospital ethics committee approved our study (number 685). Informed consent was waived because the study was retrospective with de-identified data.

Data analysis

We expressed continuous variables as mean \pm standard deviation (SD) and discrete and categorical variables as frequency. We used Fisher's exact test for comparison of relative frequencies and Welch's *t*-test for comparison of continuous variables. Using the receiver operating characteristic curve and the outcome variable of response to chemotherapy, we selected the optimal cut-off values of PNI that provided the closest point to the left upper hand corner of the graph, and then divided our patients into two groups. We compared the survival times by the Kaplan–Meier method and the log-rank test. We used the Cox proportional hazard model in order to investigate the association between biomarkers and PFS or OS. We included all variables with a *P* value <0.1 in univariate analysis in the subsequent multivariate analyses. The results were described as hazard ratios (HR) and 95% confidence interval (CI). A *P* value <0.05 was defined as statistically significant. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).¹⁵

Results

During the study period, 104 patients with stage IIIB or IV SCLC received chemotherapy. Among them, seven patients were excluded from the analysis due to lack of pretreatment albumin value. Thus, 97 patients met the inclusion and exclusion criteria. As of the data cut-off date, 6 patients were still alive, 13 were lost to follow-up, 78 were confirmed dead and

88 had experienced progressive disease during or after first-line chemotherapy. Concurrent with first-line chemotherapy, five patients received palliative radiotherapy. Three patients were palliated by thoracic radiotherapy for superior vena cava syndromes or tracheal stenosis, and two were treated for sciatica by lumbar irradiation.

In order to divide our patients into two groups, receiver operating characteristic curve analysis defined 44.3 (sensitivity 0.59, specificity 0.59, area under the curve 0.60, 95% CI 0.47–0.72) as the optimal cut-off value for PNI. Patients with mGPS 0–1 had better ECOG-PS ($P=0.02$) and higher body mass index (23.5 ± 3.7 vs 21.3 ± 4.2 , $P=0.02$) than those with mGPS 2. Patients with high PNI (≥ 44.3)

had better ECOG-PS ($P<0.01$) and higher body mass index (24.1 ± 3.6 vs 21.2 ± 3.8 , $P<0.01$). They were likely to receive cisplatin-based first-line regimen ($P=0.02$) and second-line chemotherapy ($P=0.01$). Compared with patients with mGPS 2, those with mGPS 0–1 had higher serum albumin levels and lower CRP values. Patients with high PNI (≥ 44.3) had higher absolute lymphocyte counts, higher serum albumin levels and lower CRP levels than those with low PNI (<44.3) (Table 1).

The OS of patients with mGPS 0–1 and high PNI (≥ 44.3) was significantly longer than that of those with mGPS 2 and low PNI (<44.3) (Figure 1). There was no significant difference in PFS according to mGPS and PNI (Figure 2).

Table 1 Clinical manifestations according to mGPS and PNI at first-line chemotherapy

Variables	All patients	mGPS		P-value	PNI		P-value
		0–1	2		Low (<44.3)	High (≥ 44.3)	
Patients (N)	97	65	32		46	51	
Background							
Age (years), mean \pm SD	70.5 \pm 8.7	70.0 \pm 8.8	71.7 \pm 8.4	0.36 ^a	72.3 \pm 7.5	69.0 \pm 9.4	0.06 ^a
Sex, male/female (n)	77/20	51/14	26/6	1.00 ^b	38/8	39/12	0.62 ^b
Stage IIIB/IV (n)	18/79	14/51	4/28	0.41 ^b	6/40	12/39	0.20 ^b
Extrathoracic distant metastasis (n)							
Brain	14	9	5	1.00 ^b	6	8	0.78 ^b
Liver	29	21	8	0.49 ^b	14	15	1.00 ^b
Bone	15	9	6	0.56 ^b	8	7	0.78 ^b
Adrenal gland	12	6	6	0.20 ^b	9	3	0.06 ^b
ECOG-PS 0–1/2/3 (n)	66/20/11	47/15/3	19/5/8	0.02 ^b	26/9/11	40/11/0	<0.01 ^b
Smoking status							
NS or Ex/CS (n)	30/67	19/46	11/21	0.65 ^b	13/33	17/34	0.66 ^b
BMI (kg/m ²), mean \pm SD	22.7 \pm 4.0	23.5 \pm 3.7	21.3 \pm 4.2	0.02 ^a	21.2 \pm 3.8	24.1 \pm 3.6	<0.01 ^a
Treatment							
First-line regimen (n)							
CDDP/CBDCA	21/76	17/48	4/28	0.19 ^b	5/41	16/35	0.02 ^b
VP-16/CPT-11	82/15	52/13	30/2	0.13 ^b	42/4	40/11	0.10 ^b
Second-line, yes/no (n)	57/40	42/23	15/17	0.13 ^b	21/25	36/15	0.01 ^b
Response to first-line regimen (n)							
Complete response	3	3	0		0	3	
Partial response	60	41	19		26	34	
Stable disease	14	9	5		9	5	
Progressive disease	12	10	2		5	7	
Not evaluated	8	2	6		6	2	
RR, % (95% CI)	64.9 (54.6–74.4)	67.7 (54.9–78.8)	59.4 (40.6–76.3)	0.50 ^b	56.5 (41.1–71.1)	72.5 (58.3–84.1)	0.14 ^b
DCR, % (95% CI)	79.4 (70.0–86.9)	81.5 (70.0–90.1)	75.0 (56.6–88.5)	0.59 ^b	76.1 (61.2–87.4)	82.4 (69.1–91.6)	0.46 ^b
Laboratory data, mean \pm SD							
Lym ($\times 10^3/\mu\text{L}$)	1.6 \pm 0.7	1.7 \pm 0.7	1.5 \pm 0.8	0.36 ^a	1.2 \pm 0.6	2.0 \pm 0.6	<0.01 ^a
Albumin (g/dL)	3.5 \pm 0.6	3.9 \pm 0.3	2.9 \pm 0.4	<0.01 ^a	3.1 \pm 0.5	3.9 \pm 0.4	<0.01 ^a
CRP (mg/dL)	3.1 \pm 5.4	1.3 \pm 2.2	6.9 \pm 7.6	<0.01 ^a	4.9 \pm 7.0	1.6 \pm 2.5	<0.01 ^a

Notes: ^aWelch's t-test, ^bFisher's exact test.

Abbreviations: BMI, body mass index; CBDCA, carboplatin; CDDP, cisplatin; CPT-11, irinotecan; CI, confidence interval; CRP, C-reactive protein; CS, current smoker; DCR, disease control rate; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; Ex, ex-smoker, Lym, lymphocyte count; mGPS, modified Glasgow prognostic score; NS, never smoker, PNI, prognostic nutritional index; RR, response rate; SD, standard deviation; VP-16, etoposide.




Figure 1 Kaplan–Meier curves of overall survival according to mGPS and PNI.

Abbreviations: CI, confidence interval; mGPS, modified Glasgow prognostic score; n, number of patients; PNI, prognostic nutritional index.

Univariate Cox hazard analysis revealed the following factors to be favorable prognostic markers (Table 2): for longer OS – no brain metastasis (HR 1.98, 95% CI 1.03–3.81, $P=0.04$), no liver metastasis (HR 1.73, 95% CI 1.04–2.89, $P=0.03$), no adrenal

gland metastasis (HR 1.85, 95% CI 1.01–3.40, $P=0.046$), better ECOG-PS (HR 3.33, 95% CI 2.05–5.41, $P<0.01$), higher albumin (HR 0.41, 95% CI 0.26–0.64, $P<0.01$), lower LDH ($\times 10^{-2}$) (HR 1.21, 95% CI 1.08–1.37, $P<0.01$), lower ALP ($\times 10^{-2}$)




Figure 2 Kaplan–Meier curves of PFS according to mGPS and PNI.

Abbreviations: CI, confidence interval; mGPS, modified Glasgow prognostic score; n, number of patients; PFS, progression-free survival; PNI, prognostic nutritional index.

(HR 1.08, 95% CI 1.01–1.16, $P=0.04$), lower CRP (HR 1.05, 95% CI 1.01–1.09, $P=0.02$), mGPS 0, 1 (HR 1.92, 95% CI 1.19–3.07, $P=0.01$) and higher PNI ($\times 10^{-1}$) (HR 0.51, 95% CI 0.35–0.73, $P<0.01$); for longer PFS – no brain metastasis (HR

2.03, 95% CI 1.08–3.83, $P=0.03$), no adrenal gland metastasis (HR 2.05, 95% CI 1.04–4.06, $P=0.04$), better ECOG-PS (HR 2.00, 95% CI 1.27–3.16, $P<0.01$), higher sodium concentration ($\times 10^{-1}$) (HR 0.56, 95% CI 0.36–0.86, $P<0.01$), higher albumin

Table 2 Univariate Cox hazard analysis of factors associated with OS and PFS

Variables	OS			PFS		
	HR	95% CI	P-value	HR	95% CI	P-value
Age (years)						
<75 vs ≥75	1.11	0.69–1.78	0.67	1.23	0.79–1.92	0.36
Sex						
Female vs male	0.87	0.50–1.49	0.61	1.17	0.69–1.96	0.57
Stage						
IIIB vs IV	1.41	0.78–2.52	0.25	1.11	0.65–1.90	0.71
Extrathoracic distant metastasis						
Brain	1.98	1.03–3.81	0.04	2.03	1.08–3.83	0.03
Liver	1.73	1.04–2.89	0.03	1.19	0.74–1.93	0.47
Bone	1.85	1.01–3.40	0.046	1.30	0.73–2.31	0.37
Adrenal gland	1.97	0.97–4.00	0.06	2.05	1.04–4.06	0.04
Smoking						
Ex, NS vs CS	0.94	0.59–1.53	0.82	0.87	0.56–1.36	0.54
ECOG-PS						
0–1 vs 2–4	3.33	2.05–5.41	<0.01	2.00	1.27–3.16	<0.01
BMI (kg/m ²)						
≥18.5 vs <18.5	1.70	0.93–3.11	0.09	1.45	0.80–2.64	0.22
Platinum based						
CDDP vs CBDCA	1.40	0.78–2.51	0.26	1.50	0.88–2.56	0.14
Partner drugs						
CPT-11 vs VP-16	1.51	0.77–2.96	0.23	1.89	1.00–3.59	0.05
Hemoglobin (g/dL)	0.90	0.80–1.02	0.09	0.92	0.82–1.04	0.17
RDW (%)	1.03	0.83–1.28	0.79	1.13	0.93–1.38	0.22
Ccr (mL/min) (×10 ⁻¹)	0.88	0.76–1.01	0.07	0.92	0.81–1.05	0.21
Sodium (mEq/L) (×10 ⁻¹)	0.65	0.40–1.06	0.08	0.56	0.36–0.86	<0.01
Albumin (g/dL)	0.41	0.26–0.64	<0.01	0.59	0.40–0.88	0.01
LDH (IU/L) (×10 ⁻²)	1.21	1.08–1.37	<0.01	1.12	1.01–1.24	0.04
ALP (IU/L) (×10 ⁻²)	1.08	1.01–1.16	0.04	1.10	1.02–1.19	0.02
CRP (mg/dL)	1.05	1.01–1.09	0.02	1.05	1.01–1.09	0.02
mGPS						
0, 1 vs 2	1.92	1.19–3.07	0.01	1.47	0.95–2.29	0.09
PNI (×10 ⁻¹)	0.51	0.35–0.73	<0.01	0.72	0.52–0.98	0.04

Abbreviations: ALP, alkaline phosphatase; BMI, body mass index; CBDCA, carboplatin; Ccr, creatinine clearance; CDDP, cisplatin; CI, confidence interval; CPT-11, irinotecan; CRP, C-reactive protein; CS, current smoker; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; Ex, ex-smoker; HR, hazard ratio; LDH, lactate dehydrogenase; mGPS, modified Glasgow prognostic score; NS, never smoker; OS, overall survival; PFS, progression-free survival; PNI, prognostic nutritional index; RDW, red cell distribution width; VP-16, etoposide.

(HR 0.59, 95% CI 0.40–0.88, $P=0.01$), lower LDH (×10⁻²) (HR 1.12, 95% CI 1.01–1.24, $P=0.04$), lower ALP (×10⁻²) (HR 1.10, 95% CI 1.02–1.19, $P=0.02$), lower CRP (HR 1.05, 95% CI 1.01–1.09, $P=0.02$) and higher PNI (×10⁻¹) (HR 0.72, 95% CI 0.52–0.98, $P=0.04$).

Multivariate analyses found mGPS 0–1 (HR 2.34, 95% CI 1.27–4.31, $P<0.01$) and higher PNI (×10⁻¹) (HR 0.50, 95% CI 0.31–0.75, $P<0.01$) to be favorable prognostic factors for longer OS, in addition to absence of brain metastasis and ECOG-PS (Table 3). Neither mGPS nor PNI was a prognostic factor for PFS (Table 4).

Discussion

This study demonstrated that mGPS and PNI are useful as prognostic factors for OS in advanced SCLC treated with the

standard first-line regimen of platinum-based chemotherapy. We demonstrated that these simple and user-friendly prognostic tools are useful for patients with advanced SCLC treated with chemotherapy alone.

Both mGPS and PNI were expected to be independent prognostic factors for OS in patients with SCLC treated with chemotherapy alone. We evaluated this by two means: first, multivariate Cox proportional hazard analysis detected both biomarkers as independent prognostic factors; second, Kaplan–Meier curves and log-rank tests showed that OS in patients with mGPS 2 and low PNI (<44.3) was significantly lower than that of patients with mGPS 0–1 and high PNI (≥44.3). Our results were similar to some previous studies, but different from other studies (Table 5). Two studies showed mGPS as an independent prognostic factor for OS in

Table 3 Multivariate Cox hazard analysis of the association between OS and mGPS or PNI

Variables	mGPS			PNI		
	HR	95% CI	P-value	HR	95% CI	P-value
Brain metastasis	2.91	1.23–6.84	0.01	3.82	1.57–9.31	<0.01
Liver metastasis	1.07	0.55–2.08	0.85	1.41	0.72–2.76	0.31
Bone metastasis	1.46	0.69–3.07	0.32	1.60	0.75–3.42	0.22
Adrenal gland metastasis	1.04	0.40–2.69	0.94	0.76	0.28–2.07	0.59
ECOG-PS						
0–1 vs 2–4	4.11	2.20–7.67	<0.01	3.67	1.96–6.85	<0.01
BMI (kg/m ²)						
≥18.5 vs <18.5	1.19	0.52–2.73	0.68	1.30	0.57–2.94	0.53
Hemoglobin (g/dL)	1.13	0.95–1.34	0.17	1.15	0.97–1.36	0.11
Ccr (mL/min) (×10 ⁻¹)	0.97	0.81–1.16	0.74	1.01	0.84–1.21	0.96
Sodium (mEq/L) (×10 ⁻¹)	0.82	0.47–1.43	0.49	0.99	0.57–1.73	0.98
LDH (IU/L) (×10 ⁻²)	1.07	0.91–1.25	0.44	1.06	0.89–1.26	0.54
ALP (IU/L) (×10 ⁻²)	1.06	0.94–1.20	0.32	1.03	0.91–1.15	0.66
CRP (mg/dL)	NA	NA	NA	1.05	0.99–1.11	0.13
mGPS						
0, 1 vs 2	2.34	1.27–4.31	<0.01	NA	NA	NA
PNI (×10 ⁻¹)	NA	NA	NA	0.50	0.31–0.78	<0.01

Abbreviations: ALP, alkaline phosphatase; BMI, body mass index; Ccr, creatinine clearance; CI, confidence interval; CRP, C-reactive protein; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; LDH, lactate dehydrogenase; mGPS, modified Glasgow prognostic score; NA, not applicable; OS, overall survival; PNI, prognostic nutritional index.

Table 4 Multivariate Cox hazard analysis of the association between PFS and mGPS or PNI

Variables	mGPS			PNI		
	HR	95% CI	P-value	HR	95% CI	P-value
Brain metastasis	1.98	0.93–4.23	0.08	2.22	1.02–4.83	0.04
Adrenal gland metastasis	1.29	0.53–3.16	0.57	1.10	0.43–2.79	0.85
ECOG-PS						
0–1 vs 2–4	1.69	1.04–2.76	0.04	1.76	1.06–2.91	0.03
Partner drugs						
CPT-11 vs VP-16	1.41	0.71–2.81	0.32	1.39	0.68–2.84	0.37
Sodium (mEq/L) (×10 ⁻¹)	0.60	0.37–0.98	0.04	0.64	0.39–1.06	0.08
LDH (IU/L) (×10 ⁻²)	1.04	0.92–1.18	0.54	1.02	0.90–1.16	0.73
ALP (IU/L) (×10 ⁻²)	1.06	0.97–1.17	0.21	1.06	0.96–1.18	0.23
CRP (mg/dL)	NA	NA	NA	1.03	0.98–1.08	0.28
mGPS						
0, 1 vs 2	1.05	0.64–1.71	0.85	NA	NA	NA
PNI (×10 ⁻¹)	NA	NA	NA	1.02	0.70–1.49	0.92

Abbreviations: ALP, alkaline phosphatase; CI, confidence interval; CPT-11, irinotecan; CRP, C-reactive protein; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; LDH, lactate dehydrogenase; mGPS, modified Glasgow prognostic score; NA, not applicable; PFS, progression-free survival; PNI, prognostic nutritional index; VP-16, etoposide.

Table 5 Review of multivariate analyses for prediction of survival outcomes in patients with SCLC

Reference	Patients (number) Total/ED/chemo/ TRT	Multivariate analyses							
		Outcome variables	Explanatory variables						
		Age	Sex	Stage	PS	LDH	Index type		
Hong et al ⁸	724/323/724/271	OS	N	N	Y	Y	Y	PNI	Y
Hong et al ⁷	919/367/760/ND	OS	N	N	Y	N	Y	PNI	N
Zhou et al ⁶	359/196/359/166	OS	N	Y	Y	Y	Y	mGPS	Y
Kurishima et al ¹⁶	319/216/276/ND	OS	N	NE	Y	N	NE	mGPS	Y
Our study	96/78/96/0	OS	NE	NE	NE	Y	N	mGPS, PNI	Y
		PFS	NE	NE	NE	Y	N	mGPS, PNI	N

Abbreviations: chemo, chemotherapy; ED, extensive disease; LDH, lactate dehydrogenase; mGPS, modified Glasgow prognostic score; N, not significant; ND, not described; NE, not evaluated; OS, overall survival; PFS, progression-free survival; PNI, prognostic nutritional index; PS, performance status; SCLC, small cell lung cancer; TRT, thoracic radiotherapy; Y, statistically significant.

SCLC patients.^{6,16} Although their patient backgrounds were different from ours, their result was consistent with ours. Compared with our study, including 33% (n=32) of mGPS 2, the proportions of mGPS 2 were much lower in those two previous studies: a Chinese and a Japanese study included only 3.1% (n=11)⁶ and 22.9% (n=73),¹⁶ respectively. Unlike our study that enrolled patients treated with chemotherapy alone, the Chinese study included 46.2% of patients treated with thoracic radiotherapy⁶ and the Japanese study included 13.5% patients treated with supportive care alone.¹⁶

Use of PNI as a prognostic factor for OS in SCLC is controversial. There have been two studies evaluating PNI as a prognostic factor for SCLC. One Chinese study demonstrated that PNI was a significant prognostic factor, independent of stage, performance status and LDH.⁸ This study and ours detected PNI and PS as common independent prognostic factors. Another Chinese study included 919 patients, but failed to find PNI and PS as independent prognostic factors by multivariate analysis. In that study, patients with PNI ≥ 45 survived significantly longer than those with PNI < 45 .⁷

As a predictive marker for the efficacy of platinum-based first-line chemotherapy for SCLC, neither mGPS nor PNI was promising. In addition to a statistically insignificant difference in PFS between mGPS 0–1 vs 2 and high vs low PNI groups, neither mGPS nor PNI was found to be a significant predictive factor by multivariate analysis. To our knowledge, there are no studies investigating the association of mGPS and PNI with the efficacy of chemotherapy.

Our study has several limitations. First, it was a single-centered, small-scale and retrospective study. Moreover, 13% of patients were lost to follow-up. The small number of patients and the high proportion lost to follow-up may account for the failure to identify the two biomarkers as significant predictive markers for the efficacy of chemotherapy. By contrast, both mGPS and PNI may be true prognostic markers for OS, because, despite the small size of the study, these indices were statistically significant and clinically relevant. Multicenter, prospective, large-scale studies should be conducted to validate this result. Second, patient selection was based on the availability of pretreatment blood tests. Our study excluded 6.7% of patients (7/104) due to lack of pretreatment laboratory data, a number that was much lower than reported in previous studies. Two Chinese studies excluded 22% (101/460)⁶ and 40% (492/1216)⁸ of SCLC patients during selection. Hong et al excluded 12% (146/1216) of patients owing to incomplete laboratory data.⁸ Serum albumin measurement is not routine in clinical practice.

Conclusion

This was a small retrospective study, but we found that pretreatment mGPS and PNI were independent prognostic factors for OS in patients with advanced SCLC treated with chemotherapy. The pretreatment assessment of mGPS and PNI may be useful for identification of patients with poor prognosis. We recommend pretreatment testing for CRP, serum albumin and absolute lymphocyte count.

Acknowledgments

We are grateful to Son-Ho Kim, Yuki Nakatani, Narumi Noda, Kanako Nishimatsu and Shouko Ikuta, Saori Ikebe and Hideyasu Okada at the Department of Respiratory Medicine, Osaka Police Hospital, for their detailed medical records, diagnosis, treatment and care of their patients.

Disclosure

The authors report no conflicts of interest in this work.

References

- Kinoshita FL, Ito Y, Nakayama T. Trends in lung cancer incidence rates by histological type in 1975–2008: A Population-Based Study in Osaka, Japan. *J Epidemiol*. 2016;26(11):579–586.
- Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. *Br J Cancer*. 2003;89(6):1028–1030.
- McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. *Proc Nutr Soc*. 2008;67(3):257–262.
- McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. *Int J Colorectal Dis*. 2007;22(8):881–886.
- Onodera T, Goseki N, Kosaki G. [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. *Nihon Geka Gakkai Zasshi*. 1984;85(9):1001–1005. Japanese.
- Zhou T, Hong S, Hu Z, et al. A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer. *Tumour Biol*. 2015;36(1):337–343.
- Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. *Tohoku J Exp Med*. 2015;236(4):297–304.
- Hong S, Zhou T, Fang W, et al. The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients. *Tumour Biol*. 2015;36(5):3389–3397.
- Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. *Ann Thorac Cardiovasc Surg*. 2009;15(1):4–9.
- Green RA, Humphrey E, Close H, Patno ME. Alkylating agents in bronchogenic carcinoma. *Am J Med*. 1969;46(4):516–525.
- Common Toxicity Criteria (CTC), CTC Version 2.0; 1999. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf. Accessed October 28, 2017.
- Ando Y, Minami H, Saka H, Ando M, Sakai S, Shimokata K. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing. *Br J Cancer*. 1997;76(8):1067–1071.

13. Proctor MJ, Talwar D, Balmar SM, et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. *Br J Cancer*. 2010;103(6):870–876.
14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45(2):228–247.
15. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. *Bone Marrow Transplant*. 2013;48(3):452–458.
16. Kurishima K, Watanabe H, Ishikawa H, Satoh H, Hizawa N. Modified glasgow prognostic score in patients with small-cell lung cancer. *Mol Clin Oncol*. 2017;7(1):121–124.

Lung Cancer: Targets and Therapy

Publish your work in this journal

Lung Cancer: Targets and Therapy is an international, peer-reviewed, open access journal focusing on lung cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology, detection and screening; Cellular research and biomarkers; Identification of biotargets and agents with novel

Submit your manuscript here: <https://www.dovepress.com/lung-cancer-targets--therapy-journal>

mechanisms of action; Optimal clinical use of existing anticancer agents, including combination therapies; Radiation and surgery; Palliative care; Patient adherence, quality of life, satisfaction; Health economic evaluations. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress